ArticleSleep advances : a journal of the Sleep Research Society2026
Genome-wide association study of restless legs syndrome in end-stage renal disease.
Article in Sleep advances : a journal of the Sleep Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study Objectives: Restless legs syndrome (RLS) is predominantly idiopathic (iRLS), with a prevalence of 2%-10% in Europe. In end-stage renal disease patients (ESRD), uremic RLS (uRLS) is substantially more prevalent, with estimates of 24%-28%. Its pathophysiology has not been fully uncovered. Therefore, we investigated potential genetic and phenotypic risk factors for uRLS. Materials and Methods: We performed case-control genome-wide association studies (GWAS) on ESRD patients with and without RLS from two German and one Greek ESRD study populations (cases/controls: 186/356, 80/176, 134/357). We applied a polygenic risk score (PRS) for iRLS to four groups: uRLS cases, uremic controls, a group of iRLS cases and European 1000G individuals. Additionally, we investigated RLS associations with phenotype data available in one German dataset. Results: No SNP reached genome-wide significance in any single dataset or meta-analyses. The mean iRLS PRS was significantly higher in uRLS cases compared to uremic controls ( Conclusions: Our findings indicate that uRLS and iRLS share a substantial part of their genetic architecture, while also pointing to candidate signals specific to uRLS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.